Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy

Cytokine

Volumn 59, Issue 1, 2012, Pages 3-9

  Wang, Xiao Min ^a   Lehky, Tanya J ^b   Brell, Joanna M ^c   Dorsey, Susan G ^d  

^a NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

Author keywords

Biomarkers; Chemotherapy; Cytokines; Peripheral neuropathy

Indexed keywords

ACETYLCARNITINE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; AV 1013; BORTEZOMIB; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CELECOXIB; CISPLATIN; CYTOKINE; IBUDILAST; IBUPROFEN; ILOMASTAT; INDOMETACIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MELATONIN; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; PROPENTOFYLLINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALLODYNIA; ANTIINFLAMMATORY ACTIVITY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; GENE THERAPY; HUMAN; HYPERALGESIA; IMMUNOMODULATION; INFLAMMATION; NEUROIMMUNOLOGY; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTIVE RECEPTOR; NONHUMAN; OTOTOXICITY; PACLITAXEL ACUTE PAIN SYNDROME; PATHOGENESIS; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE RISK; REVIEW; SURVIVAL RATE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; MOLECULAR TARGETED THERAPY; NEURALGIA; NOCICEPTORS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84861673585     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.03.027     Document Type: Review

References (83)

1. Brittany M.D. Chemotherapy-Induced Peripheral Neuropathy. NCI Cancer Bull 2010, 7.
2. Mielke S., Sparreboom A., Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006, 42:24-30.
3. Masellis A.M., Sielaff T.D., Bender G.P. Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol 2009, 14:478-481.
4. Jacobs J.M. Vascular permeability and neurotoxicity. Environ Health Perspect 1978, 26:107-116.
5. Pettersson C.A., Sharma H.S., Olsson Y. Vascular permeability of spinal nerve roots. A study in the rat with Evans blue and lanthanum as tracers. Acta Neuropathol 1990, 81:148-154.
6. Cavaletti G., Cavalletti E., Oggioni N., Sottani C., Minoia C., D'Incalci M., et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000, 21:389-393.
7. Brown W.F., Snow R. Patterns and severity of conduction abnormalities in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1991, 54:768-774.
8. Weimer L.H. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003, 3:86-92.
9. Boyette-Davis J., Xin W., Zhang H., Dougherty P.M. Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011, 152:308-313.
10. Burakgazi A.Z., Messersmith W., Vaidya D., Hauer P., Hoke A., Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011, 77:980-986.
11. Pachman D.R., Barton D.L., Watson J.C., Loprinzi C.L. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011, 90:377-387.
12. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27-46.
13. Flatters S.J., Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006, 122:245-257.
14. Bennett G.J., Liu G.K., Xiao W.H., Jin H.W., Siau C. Terminal arbor degeneration-a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci 2011, 33:1667-1676.
15. Liu C.C., Lu N., Cui Y., Yang T., Zhao Z.Q., Xin W.J., et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010, 6:76.
16. Sengottuvel V., Leibinger M., Pfreimer M., Andreadaki A., Fischer D. Taxol facilitates axon regeneration in the mature CNS. J Neurosci 2011, 31:2688-2699.
17. Tanner K.D., Levine J.D., Topp K.S. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998, 395:481-492.
18. Topp K.S., Tanner K.D., Levine J.D. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000, 424:563-576.
19. Polomano R.C., Mannes A.J., Clark U.S., Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001, 94:293-304.
20. Umapathi T., Tan W.L., Loke S.C., Soon P.C., Tavintharan S., Chan Y.H. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve 2007, 35:591-598.
21. Viader A., Golden J.P., Baloh R.H., Schmidt R.E., Hunter D.A., Milbrandt J. Schwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve function. J Neurosci 2011, 31:10128-10140.
22. Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Kalofonos H.P., Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 2005, 252:1459-1464.
23. Abbadie C. Chemokines, chemokine receptors and pain. Trends Immunol 2005, 26:529-534.
24. Zhang J.M., An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin 2007, 45:27-37.
25. Keswani S.C., Polley M., Pardo C.A., Griffin J.W., McArthur J.C., Hoke A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003, 54:287-296.
26. Cunha T.M., Verri W.A., Silva J.S., Poole S., Cunha F.Q., Ferreira S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Nat Acad Sci USA 2005, 102:1755-1760.
27. Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10:1361-1368.
28. Sommer C., Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004, 361:184-187.
29. Wang X.M., Hamza M., Wu T.X., Dionne R.A. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: correlation to clinical pain. Pain 2009, 142:275-283.
30. Uceyler N., Kafke W., Riediger N., He L., Necula G., Toyka K.V., et al. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology 2010, 74:1806-1813.
31. Watkins L.R., Maier S.F. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002, 82:981-1011.
32. Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
33. Tofaris G.K., Patterson P.H., Jessen K.R., Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci. 2002, 22:6696-6703.
34. Peters C.M., Jimenez-Andrade J.M., Jonas B.M., Sevcik M.A., Koewler N.J., Ghilardi J.R., et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007, 203:42-54.
35. Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., Ghilardi J.R., Mantyh P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007, 1168:46-59.
36. Jimenez-Andrade J.M., Peters C.M., Mejia N.A., Ghilardi J.R., Kuskowski M.A., Mantyh P.W. Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett 2006, 405:62-67.
37. Nishida K., Kuchiiwa S., Oiso S., Futagawa T., Masuda S., Takeda Y., et al. Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci 2008, 99:1618-1625.
38. Krarup-Hansen A., Rietz B., Krarup C., Heydorn K., Rorth M., Schmalbruch H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 1999, 25:29-40.
39. Loprinzi C.L., Maddocks-Christianson K., Wolf S.L., Rao R.D., Dyck P.J., Mantyh P. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007, 13:399-403.
40. Loprinzi C.L., Reeves B.N., Dakhil S.R., Sloan J.A., Wolf S.L., Burger K.N., et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011, 29:1472-1478.
41. Ozturk G., Erdogan E., Anlar O., Kosem M., Taspinar M. Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine 2005, 29:31-41.
42. Campana W.M. Schwann cells: activated peripheral glia and their role in neuropathic pain. Brain Behav Immun 2007, 21:522-527.
43. Ledeboer A., Jekich B.M., Sloane E.M., Mahoney J.H., Langer S.J., Milligan E.D., et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007, 21:686-698.
44. Abraham K.E., McMillen D., Brewer K.L. The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience 2004, 124:945-952.
45. Broyl A., Corthals S.L., Jongen J.L., van der Holt B., Kuiper R., de Knegt Y., et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11:1057-1065.
46. Lees C.W., Zacharias W.J., Tremelling M., Noble C.L., Nimmo E.R., Tenesa A., et al. Analysis of germline GLI1 variation implicates hedgehog signaling in the regulation of intestinal inflammatory pathways. PLoS Med 2008, 5:e239.
47. Kim H.J., Oh G.S., Lee J.H., Lyu A.R., Ji H.M., Lee S.H., et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res 2011, 21:944-956.
48. Schafers M., Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett 2008, 437:188-193.
49. Dina O.A., Chen X., Reichling D., Levine J.D. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001, 108:507-515.
50. Alessandri-Haber N., Dina O.A., Yeh J.J., Parada C.A., Reichling D.B., Levine J.D. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 2004, 24:4444-4452.
51. Xiao W.H., Bennett G.J. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008, 135:262-270.
52. Binshtok A.M., Wang H., Zimmermann K., Amaya F., Vardeh D., Shi L., et al. Nociceptors are interleukin-1beta sensors. J Neurosci 2008, 28:14062-14073.
53. Postma T.J., Vermorken J.B., Liefting A.J., Pinedo H.M., Heimans J.J. Paclitaxel-induced neuropathy. Ann Oncol 1995, 6:489-494.
54. Einzig A.I., Wiernik P.H., Wadler S., Kaplan J., Benson L.T., Tentoramano L., et al. Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Invest New Drugs 1998, 16:29-36.
55. Verstappen C.C., Heimans J.J., Hoekman K., Postma T.J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003, 63:1549-1563.
56. Siau C., Xiao W., Bennett G.J. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006, 201:507-514.
57. Folgueras A.R., Valdes-Sanchez T., Llano E., Menendez L., Baamonde A., Denlinger B.L., et al. Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proc Nat Acad Sci USA 2009, 106:16451-16456.
58. Kawasaki Y., Xu Z.Z., Wang X., Park J.Y., Zhuang Z.Y., Tan P.H., et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336.
59. Schafers M., Brinkhoff J., Neukirchen S., Marziniak M., Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001, 310:113-116.
60. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
61. Shubayev V.I., Angert M., Dolkas J., Campana W.M., Palenscar K., Myers R.R. TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol Cell Neurosci 2006, 31:407-415.
62. Berger T., Malayeri R., Doppelbauer A., Krajnik G., Huber H., Auff E., et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997, 33:1393-1399.
63. Cavaletti G., Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010, 6:657-666.
64. du Bois A., Schlaich M., Luck H.J., Mollenkopf A., Wechsel U., Rauchholz M., et al. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care Cancer 1999, 7:354-361.
65. Kobayashi H., Chattopadhyay S., Kato K., Dolkas J., Kikuchi S., Myers R.R., et al. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008, 39:619-627.
66. Mika J., Osikowicz M., Makuch W., Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007, 560:142-149.
67. Nikodemova M., Duncan I.D., Watters J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006, 96:314-323.
68. Keilhoff G., Schild L., Fansa H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in bioartificial nerve grafts lacking Wallerian degeneration. Exp Neurol 2008, 212:189-200.
69. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008, 60:297-307.
70. Raghavendra V., Tanga F., DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003, 306:624-630.
71. Cata J.P., Weng H.R., Dougherty P.M. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res 2008, 1229:100-110.
72. Coutaux A., Adam F., Willer J.C., Le Bars D. Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 2005, 72:359-371.
73. Cho Y., Crichlow G.V., Vermeire J.J., Leng L., Du X., Hodsdon M.E., et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Nat Acad Sci USA 2010, 107:11313-11318.
74. Mizumura K., Sugiura T., Katanosaka K., Banik R.K., Kozaki Y. Excitation and sensitization of nociceptors by bradykinin: what do we know?. Exp Brain Res 2009, 196:53-65.
75. Feng J., Misu T., Fujihara K., Sakoda S., Nakatsuji Y., Fukaura H., et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004, 10:494-498.
76. Ledeboer A., Hutchinson M.R., Watkins L.R., Johnson K.W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007, 16:935-950.
77. Sweitzer S.M., Pahl J.L., DeLeo J.A. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 2006, 400:258-261.
78. Bujalska M., Tatarkiewicz J., Gumulka S.W. Effect of bradykinin receptor antagonists on vincristine- and streptozotocin-induced hyperalgesia in a rat model of chemotherapy-induced and diabetic neuropathy. Pharmacology 2008, 81:158-163.
79. Bujalska M., Makulska-Nowak H. Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model. Neuro Endocrinol Lett 2009, 30:144-152.
80. Lynch J.J., Wade C.L., Zhong C.M., Mikusa J.P., Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 2004, 110:56-63.
81. Bujalska M., Gumulka S.W. Effect of cyclooxygenase and nitric oxide synthase inhibitors on vincristine induced hyperalgesia in rats. Pharmacol Rep 2008, 60:735-741.
82. Cata J.P., Cordella J.V., Burton A.W., Hassenbusch S.J., Weng H.R., Dougherty P.M. Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manage 2004, 27:72-78.
83. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 2011, 50:124-131.